Good afternoon, and thank you for joining us today to discuss OptimizeRx first quarter ended March 31, 2016. With us today are the company's Chief Executive Officer, William Febbo; and its Chief Financial Officer, Doug Baker. Following their remarks, we will open the call to your questions. Before we begin, I would like to provide the company's safe harbor statements. Statements made by management during today's call may contain forward-looking statements within the definition of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Act of 1934 as amended. These forward-looking statements should not be used to make an investment decision. The words estimate, possible and seeking and similar expressions identify forward-looking statements, and they speak only to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of the new information, future events or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth and contemplated by or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject and could affect our business and financial results are included in the company's annual report on Form 10-K for the fiscal year ended December 31, 2015. This form is available on the company's website and on the SEC website at sec.gov. I would like to remind everyone that today's call is being recorded, and it will be available for replay through May 30 starting later this evening. Please see today's press release for replay instructions. Now with that, I would like to turn the call over to the Chief Financial Officer of OptimizeRx, Mr. Doug Baker. Sir, please proceed.

Thank you, Vicky, and I'd like to thank everyone else for joining us on today's call to discuss our results for the first quarter of 2016. Following my financial review, Will is going to comment on our operational performance and provide our outlook for 2016. Now turning to our financial results for the quarter. Our net revenue in the first quarter of 2016 increased 18% to $1.8 million versus $1.5 million in the same year ago quarter. The increase was due to increased promotional of pharmaceutical brands and expanded distribution channels. Operating expenses in the first quarter of 2016 were $1.2 million as compared to $800,000 in the same year ago quarter. The increase was primarily due to an increase in expenses related to growth initiatives, including investments in the company's executive and sales teams and related marketing and travel. Since the first quarter of 2015, we've hired several key executives, including a Vice President of Client Services; a Senior Vice President of Business Development; and an additional Vice President of Sales; and of course, Will, our new CEO. Our net loss in the first quarter of 2016 was $352,000 or $0.01 a share as compared to a loss of $111,000 or $0.00 per share in the same year ago quarter. Turning to the balance sheet. Our cash and cash equivalents totaled $7.5 million at March 31 as compared to $8.2 million at December 31. The decrease in cash and equivalents was due to the payout to our former CEO for shares owed to him from prior years in lieu of actually issuing those shares. Without that payout, our cash would have been increased slightly during the quarter. We also continue to operate debt free. Now with that, I'd like to turn the call over to Will.

Thanks, Doug. Thanks, everyone, for joining us today. 2.5 months into the position, I remain very positive on the opportunity we have with our clients, our channel partners, investors and the team. The first month was spent meeting with the majority of the community mentioned above and learning how they all interconnected. My hat is off to the operational team and former leadership at OptimizeRx for setting the stage for a very scalable business in a very new and evolving digital health channel. The dramatic shifts that are happening between drug manufacturers, payers, hospitals, healthcare professionals and patients are hard to predict and are hard to participate within given the complexities. The good news is OptimizeRx is well positioned with its channel partners to bring value to all constituencies through its products and services. For those of you who are new to our story, we help our clients automate their co-pay savings and trial voucher programs by using our proprietary on-demand content delivery platform. Through this platform, they're able to reach more than 250,000 healthcare providers via our network of more than 350 health -- electronic health record companies through a series of exclusive partnerships. The eCoupon or financial messaging is our dominant product through this channel. Our platform enables our clients to connect with healthcare providers at point of care. This is critical as it's hard for sales representatives to visit the healthcare providers each year. This, coupled with the fact that electronic prescriptions are likely to exceed 2 billion in 2016 and that studies indicate that 80% of physicians are more likely to prescribe a drug that has a co-pay savings card versus one that does not, allowed us to become a trusted partner bringing value across the board. These market trends and growing demand by our pharmaceutical…

[Operator Instructions] First, we'll go to Brian Murphy with Merriman Capital.

Solid quarter. And it sounds like you have a -- you have some nice momentum here. Will, it sounds like you're going to be making some pretty aggressive moves here in terms of evolving the product offering. I'm wondering with respect to the product extensions that you mentioned, I'm curious how your partnership with WPP and your closer relationships with agencies in general is informing that new product development and whether or not you think that gives you a unique view or competitive advantage into a very sort of fragmented and complex ecosystem here?

Brian, thanks. Good question. We -- yes, it's very informed by our partners and our exposure into the media companies. And for the other listeners, the media companies are trusted advisers with pharmaceutical companies generally at the brand level, and they help them determine how best to allocate their spend. And so, obviously, a lot of vendors try to get in there and present their value proposition. Well, given our partnership, we obviously have a seat at the table with the leading agencies in the world. And so when I look at -- when we look at the brands that they help manage, those that we're already tied into, yes, I see a lot of room for improvement. And what we realized through some of that learning over the last few months is we just weren't positioning ourselves to service that terribly well. So we're adjusting that with good advice and getting a strong reaction. They control a lot of the access to those budgets, and therefore because we're invited into advise and recommend campaigns, it's a tremendous opportunity for us.

Do you think those partnerships give you a good angle on capturing more of the clinical messaging business?

I do. Some of the studies -- and you can Google this because it's -- a lot of it has been published now, is -- at the end of the day, our partners enable us to bring technology to the doctors principally. And so if you're bringing something they're not interested in, that doesn't last long. So when you look at what doctors are most interested in, it's obviously efficacy. Helping their patients is number one, educating their patients and helping their patients save money. And inside the education, you bring clinical messaging and patient education. And so obviously, we don't develop drugs, right? So we can't do the first one. But the second 2 most important, we're squarely in that space. And so I feel comfortable we're enabling content to get to the healthcare provider, which gets to the patient, and that certainly helps our partners work with us a little faster because we all win in that case.

Okay, great. I'll ask one more quick one and then jump back in the queue. The large urology EHR that had the integration issues last year, is that still estimated to be back online in the second half of '16?

It is still estimated to be on in the second half, yes.

[Operator Instructions] We'll go next to Harvey Poppel with Poptech, LP.

Will, couple of things. In the past, you and your predecessor have commented about trying to upgrade the listing of the company, get it into a market where there's more liquidity and more, I guess, prestige. What's your plan on that?

Harvey, I appreciate the compliment coming from you and the support you always gave. Yes, relative to uplisting, I think we talked a little about it in the last call. I'm a big believer in -- you kind of earned that spot, and if you don't earn it and you force it, it's expensive and dilutive. So I really have my head down with the team on working on growth and really cementing an additional partnerships and distribution; because if we're attractive now and we were able to do that, we're going to be very attractive a year from now. And so I think we'll be able to entertain that. But right now, I think that would just be a distraction to me, and what we really have to do is capture market share now because it's really early.

Okay. And do you feel there's additional opportunities to exploit the existing base of brands and the EHRs that you have in terms of getting additional revenue out of that base?

Yes, that was my initial -- again, it's 2.5 months in, so I don't want to get ahead of my skis. But I do think that if we just look at what we've built for the eCoupons, financial messaging and we bring clinical messaging and brand support to that, then that's the same buyer -- the same value proposition to the same buyer with the same general partner. So that's really, I think, our most -- that's the easiest way to growth and obviously that doesn't mean we're still trying to grow distribution and get more brands. But yes, I think those 2, the clinical messaging and brand support, will give us a lift from the traditional business of eCoupon.

But is that only a one-way street? In other words, from the clients that you're currently providing eCoupons to, you could sell them additional messaging types services. But will the availability of messaging services help you attract the additional brands for eCoupon, do you think?

Absolutely. Matter of fact, the messaging is probably a bigger budget, if your roll it all up. So I think we're little late to the game on messaging. And so I think we're going to have a lot of room for growth, but it will also give us a little bit more heft in front of pharma clients because they do like it when you have more business with them; they feel more confident. So I do think it'll help us lift the eCoupon side as well, yes.

[Operator Instructions] We'll go next to Ron Jones [ph], a private investor.

And amongst the opportunities that you have, how do you rank them the first 2 or 3? I think you did a bit of that expanding budgets for brands, additional brands, additional EHRs. What are the 2 most important complementary elements?

So from my view. the -- and the team's view is we've got a really solid set of about 25 pharma clients, and we've undersold this clinical messaging product. So we're going to push hard on selling that into that same channel. So that's a priority, and there's some technology lift to enable us to do more of that ourselves working -- as opposed to working through partners. So that probably priority #1. And then just to create more of a leadership and trusted position with pharma, the brand support service is important because that allows us to really help the brand manager train their sales force on how to talk to physicians about the EHR space and also make sure their formulary is correct, which at the end of the day is critical. So I'd say those 2 are the key priorities in terms of revenue growth.

And is your return on investment here for a brand manager in good order? Got a good [indiscernible] story?

It is. As many may know, we are often asked to do an ROI; and we bring in a third party for that, large consulting firms with household names. We pull the appropriate data; they run the report, and we present back. And we've had pretty consistent ROI. And it's a blessing and a curse. The blessing is the ROI is great. The curse is there are several things they spend a lot more money on that they can't get an ROI on. So it's -- but again, we're lucky that they're coming out on the positive side.

I would think it would be more of a blessing than a curse if you can have quantitative support to what you're trying to sell.

Yes, the only thing we see sometimes is that they want -- they slow down to want to see an ROI. So that's the only negative. But they tend to -- they're -- we're starting to giving our sales team, how effective they are, they're -- convincing to let it roll while they do it. That's an improvement. And luckily, they usually come out on the good side.

And are you getting -- last question, are you getting -- do you have a goal and are you measuring it to see about getting more from -- to support individual brands?

Yes, we implemented a CRM system where we're tiering our clients and brands based on volumes. So we go after the key accounts first and have a tier system and tracking it accordingly, and incentive compensation is connected to it.

And do you have evidence that you can get more from individual brands?

Yes, we know from a macro standpoint through the agencies what the annual budget spend is, and we know what we're billing, so we can certainly -- we see room there for growth.

And last question, are you spending time trying to help Valiant?

We don't comment on specific clients, but they are -- they're 1 of the top 50. And we're happy to help them, yes.

Do you do work with them now?

Yes.

[Operator Instructions] We have no further questions at this time, so I turn the call back over to Mr. Febbo. Sir, please proceed.

Sorry, I was -- let me just see here. Well, I just want to say thank you for everyone calling in, giving us the support. I will continue to hammer as I have been for the last 2.5 months and very excited, as I said, about new products and services, the team, getting the technology shored up so we're really a best-in-class health tech company and then obviously increasing our client base and our channel partners. So with that, I appreciate your support. We all do, and look forward to talking to you in a couple of months.

I would like to remind everyone that this call will be available for replay starting later today. Please refer to today's press release for dial-in replay instructions. A webcast replay will also be available via the company's website at www.optimizerxcorp.com. Thank you for joining us today. You may now disconnect.